MediXin Group
From Strategy to Execution in Global Healthcare Markets
We support global healthcare companies in entering China,
and China-based companies in expanding globally.
Connecting China and Global Healthcare Innovation
Start Your Cross-Border Strategy →
What We Do
Our Services
MediXin delivers end-to-end services — from strategy design to execution — enabling global and China-based healthcare companies to achieve cross-border growth.
🌏

Inbound

Entering China via GBA & Hong Kong

We support global healthcare companies in entering China, with a focus on pharmaceutical and medical device sectors.

  • Early access strategy (GBA Pathway)
  • China regulatory strategy, registration & GBA policy leverage
  • Real-world evidence (RWE) for regulatory and market access
  • Market access & hospital entry
🚀

Outbound

Expanding to Global & Emerging Markets

We support China-based healthcare companies in expanding globally, with a focus on pharmaceutical and medical device sectors.

  • Global regulatory and registration pathways
  • Stepwise market entry into Hong Kong and emerging markets (e.g. ASEAN)
  • Commercialization strategy and execution
  • Cross-border partnerships and local collaboration
⚡

Execution

From Strategy to Delivery

We support cross-border healthcare projects through end-to-end execution.

  • End-to-end project execution
  • Regulatory, clinical, and commercial coordination
  • Partner identification and management

We do not stop at strategy — We deliver results

About
About MediXin

MediXin is a cross-border healthcare advisory and execution firm. We support global healthcare companies in entering China, and China-based companies in expanding internationally — from strategy to execution.

With deep expertise in China's healthcare policy, regulatory systems, and market access, MediXin translates complex environments into actionable pathways and ensures delivery through strong execution capability.

Our work focuses on enabling cross-border healthcare innovation, with particular strength in navigating China's regulatory landscape and supporting execution across Hong Kong, the Greater Bay Area, and global markets.

Leadership
Kang Wei

Kang Wei | 康韦

Founder & Strategic Lead, MediXin Group
Founder, GBAAPI | Former Managing Director, RDPAC

Kang Wei is the Founder and Strategic Lead of MediXin Group. She brings a unique combination of policy leadership, industry expertise, and execution capability.

From Policy Leadership to Execution

Former Managing Director of RDPAC. Worked closely with multinational companies and regulatory authorities.

Building Innovation Ecosystems

Founder of Greater Bay Area Alliance of Pharmaceutical Innovation (GBAAPI), connecting regulators, industry leaders, and global stakeholders.

From Strategy to Execution

Supports global healthcare companies entering China and China-based innovation expanding globally. We do not stop at strategy — we deliver results.

Industry Experience

Vice President, Fresenius Kabi China | Senior Marketing Director & BU Head, Novartis Greater China

Advisors
Annette Chiu

Annette Chiu | 赵碧琴

Regulatory Advisor

Annette Chiu is a highly experienced regulatory and medical affairs expert with over 30 years of experience across Hong Kong, China, and the Greater Bay Area. She has successfully led and accelerated the registration of more than 20 innovative products, including NCEs, biologics, and vaccines. She has extensive experience in regulatory strategy, pharmacovigilance, and GMP compliance, and has supported CFDI GMP inspections in China. Her therapeutic experience spans oncology, infectious diseases, vaccines, and chronic diseases. She also brings strong expertise in market entry strategy and engagement with regulatory authorities.

Current: Executive Director, AMERA | Former: Senior Regulatory Leader, GSK
How We Work
Our Process
Four steps from opportunity assessment to delivery — enabling cross-border healthcare strategy from end to end.
1

Opportunity Assessment

Identify the most viable pathway for market entry or expansion.

→
2

Strategy Design

Define the optimal regulatory, clinical, and commercial approach.

→
3

Execution Coordination

Work with regulators, partners, and stakeholders to implement the strategy.

→
4

Delivery & Results

Ensure successful outcomes, from registration to commercialization.

Why It Works
Why MediXin

Deep expertise in China's healthcare policy, regulatory and market access

Strong network across China, Hong Kong, the Greater Bay Area, and global markets

Proven end-to-end capability — from strategy to execution